Abstract
We retrospectively examined the antibodies to p22, a hepatitis C virus (HCV) nucleocapsid protein, and to c100-3, a HCV nonstructural protein, in donors whose blood was transfused to patients who later developed post-transfusion non-A, non-B hepatitis. Of 13 such blood donors, three seroconverted and three seroreverted with the anti-c100-3 test. In contrast, 12 of the 13 blood donors showed the same results at transfusion and follow-up, and one donor showed seroconversion with the anti-p22 assay. The follow-up study shows that the anti-p22 antibody test provides consistent results and is far more suitable for screening blood than the anti-c100-3 test.
MeSH terms
-
Antigens, Viral*
-
Blood Donors*
-
Blood Transfusion / standards*
-
Enzyme-Linked Immunosorbent Assay
-
False Negative Reactions
-
Follow-Up Studies
-
Hepacivirus / immunology*
-
Hepatitis Antibodies / blood*
-
Hepatitis C / blood
-
Hepatitis C / diagnosis
-
Hepatitis C / prevention & control
-
Hepatitis C / transmission*
-
Hepatitis C Antibodies
-
Hepatitis C Antigens
-
Humans
-
Mass Screening*
-
Predictive Value of Tests
-
Reagent Kits, Diagnostic
-
Retrospective Studies
-
Transfusion Reaction
-
Viral Core Proteins / immunology*
-
Viral Nonstructural Proteins / immunology*
Substances
-
Antigens, Viral
-
C100 protein, hepatitis C virus
-
Hepatitis Antibodies
-
Hepatitis C Antibodies
-
Hepatitis C Antigens
-
Reagent Kits, Diagnostic
-
Viral Core Proteins
-
Viral Nonstructural Proteins
-
core protein p22, Hepatitis C virus
-
nucleocapsid protein, Hepatitis C virus